A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
收藏DataCite Commons2025-06-23 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005693/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF)and to assess the safety of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis.
提供机构：
Vivli
创建时间：
2020-05-05
